CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered. Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.

Inclusion Criteria: * Diagnosis of any subtype of medulloblastoma between the ages of 3 to 22 years or between the ages of 22 to 44 years with the sonic hedgehog (SHH) subtype of medulloblastoma * Radiotherapy on or according to the SJMB12 protocol * Received radiotherapy at St. Jude Children's Research Hospital * 5 or more years since the initiation of radiation therapy and who did not have evidence of disease progression * Provision of informed consent by participant/guardian or legal representative; Assent by minor participant * Participants may choose to complete all or a subset of the proposed assessments; refusal to participate in some aspects of the study will not preclude participant inclusion * Participants must also complete enrollment on SJLIFE Exclusion Criteria: * Participants or their legal guardian/representative are unwilling or unable to provide written informed consent. * Participants who had relapsed or refractory disease during or following completion of treatment for medulloblastoma